Male reproductive system disorder

This early-phase study tests a personalized vaccine made from a patient's own immune cells and tumor markers. It aims to help the immune system attack advanced prostate cancer that has stopped responding to standard treatments. About 9 to 18 men will receive four doses over eight…

This phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay can…

This study is testing whether adding a DNA vaccine (pTVG-AR) and immune checkpoint blockers (nivolumab or cemiplimab) to standard hormone therapy can improve outcomes for men with newly diagnosed, high-risk prostate cancer. About 60 participants will receive different combination…

This study looks at how prostate cancer treatments, especially hormone therapy, affect heart health. It includes two parts: one that follows men over time to track heart problems, and another that tests whether a program of healthy eating, exercise, smoking cessation, and medicat…

This early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.

This study tests a precise radiation technique called adaptive SBRT for men with high-risk or unfavorable intermediate-risk prostate cancer. The treatment targets the prostate and pelvic lymph nodes while giving an extra radiation boost to tumor spots seen on MRI. The goal is to …

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This phase 2 trial tests whether giving hormone therapy before prostate surgery helps men with high-risk prostate cancer recover erectile function better. About 90 men will receive either apalutamide alone or a combination of apalutamide, abiraterone, GnRH agonist, and prednisone…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targ…

This study tests whether a higher dose of proton radiation, focused on tumors seen on MRI, can better control high-risk prostate cancer. About 100 participants will receive radiation over 8-9 weeks, plus hormone therapy for 18 months. The goal is to lower the chance of cancer ret…

This study compares two types of radiation therapy for men with favorable or low-tier intermediate risk prostate cancer: low dose rate (LDR) brachytherapy, which uses permanent radioactive seeds, and high dose rate (HDR) brachytherapy, which uses temporary radioactive material. T…

This phase 3 trial tests whether adding darolutamide to standard hormone therapy (ADT) after prostate removal surgery can better prevent cancer from spreading in men with high-risk prostate cancer. The study enrolls 27 men who had their prostate removed and are at highest risk of…

This study tests a combination of two drugs—cabozantinib (a targeted therapy) and 177Lu-PSMA-617 (a radioactive drug)—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if the combination can slow cancer gr…

This study looks at whether adding a precise type of radiation (SBRT) to intermittent hormone therapy can better control prostate cancer that has spread to a few places in the body. The trial involves 60 men whose cancer was detected by a special PET scan but not by standard scan…

This Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …

This study is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to other cancer treatments can help men with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and no longer responds to hormone therapy. About 1,…

This study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…

This phase 3 trial tests whether treatment for high-risk prostate cancer can be personalized based on a patient's genetic risk score. For those with a low genetic risk, a shorter course of hormone therapy plus radiation may be as effective as the standard 24-month treatment, with…

This study compares standard fluid management to a newer method using the Plethysmography Variability Index (PVI) during prostate surgery for enlarged prostate. The goal is to see if PVI-guided care reduces risks like fluid overload or low blood pressure. Fifty-eight men aged 50-…

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This phase II trial tests whether adding the hormone-blocking drug relugolix to standard radiation therapy can slow cancer growth in men with prostate cancer that has spread to a few other spots in the body (oligometastatic). About 194 participants will receive either radiation a…

This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The goal is to lower testosterone levels to control the cancer. About 55 men will receive different doses to find the best one. This is not a cure, but a way to manage the diseas…

This early-stage study tests whether combining a radioactive drug (177Lu-PSMA-617) with precise radiation therapy (SBRT) is safe for men with hormone-sensitive prostate cancer that has spread to a few other spots in the body. The drug seeks out and attacks cancer cells, while the…

This early study tests the safety of TheraSphere PCa, tiny radioactive glass beads injected into the prostate to treat localized prostate cancer. The trial involves 36 men with favorable intermediate-risk cancer and aims to find the maximum safe radiation dose. Researchers will m…

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…

This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see…

This study tests a biodegradable balloon, called a rectal spacer, placed between the prostate and rectum before radiation therapy for prostate cancer. The goal is to see if it safely reduces radiation exposure to the rectum, potentially lowering side effects. Up to 150 men with l…

This phase III trial tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to nearby lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus …

This phase III trial uses a genetic test (Decipher score) to personalize treatment for men with unfavorable intermediate-risk prostate cancer. For those with a high genetic risk, the study tests adding darolutamide to standard hormone therapy and radiation. For those with low gen…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer wil…

This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…

This phase 3 study tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) can delay cancer progression in men with high-risk biochemical recurrence of prostate cancer. About 985 men whose PSA levels rose after initial treatment will receive either darolutami…

This phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants r…

This phase II trial tests whether green tea catechins (GTC) can prevent low-risk prostate cancer from progressing in men on active surveillance. 360 participants will receive either GTC or a placebo daily. The study measures changes in a tumor growth marker (Ki-67) in biopsy samp…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early-stage study tests a new drug called ABBV-969 in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the best dose. About 230 participants worldwide will receive the drug…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This study tests whether adding olaparib to standard abiraterone therapy can slow the growth of metastatic castration-resistant prostate cancer better than abiraterone alone. About 110 men who have not had chemotherapy or newer hormone drugs for this stage of cancer will particip…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase 2 trial tests whether adding the chemotherapy cabazitaxel to standard hormone therapy (abiraterone) can better control advanced prostate cancer that has spread and stopped responding to initial treatment. The study involves 223 men whose cancer progressed after docetax…

This study aimed to see if the drug clomiphene citrate could help men with a condition called non-obstructive azoospermia, where the body produces little to no sperm. The plan was to give the drug or a placebo for nine months, then check if sperm could be found in the semen or th…

This study looks at whether a whole-food, plant-based diet can help overweight or obese men with prostate cancer who are on hormone therapy (ADT) control their weight and reduce inflammation. About 76 men will either receive free plant-based meals at home or standard nutrition ad…

This study looks at how well the body handles a radioactive drug (lutetium vipivotide tetraxetan) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if different levels of kidney function change how the drug spr…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men …

This early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing healthy t…

This phase II trial is testing a shorter course of proton beam radiation (hypofractionated) in 241 men with early-stage prostate cancer that hasn't spread. The goal is to see if this precise radiation can kill cancer cells while causing fewer bowel and bladder side effects compar…

This phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 particip…

This phase 2 trial is testing whether adding the drug sunitinib to standard hormone therapy can shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with localized but aggressive prostate cancer will receive sunitinib pills plus a hormone block…

This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …

This study is a registry that collects real-world information on the safety and effectiveness of Boston Scientific penile implants for erectile dysfunction. It will enroll 450 men who are already scheduled to receive the implant. Researchers will track changes in erectile functio…

This study compares two surgical methods for treating benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The trial involves 140 men aged 50-80 with prostates of 80 mL or larger who are candidates for holmium laser enucleation. One group receives the …

This study tests a gel called SpaceIT that is placed between the prostate and rectum before radiation therapy for prostate cancer. The gel acts as a spacer to reduce radiation reaching the rectum, potentially lowering side effects. About 230 adults with low- to intermediate-risk …

This study compares a minimally invasive water vapor treatment (REZŪM) to taking two drugs together for men with an enlarged prostate that didn't get better with one drug. It includes 155 sexually active men aged 45 and older. The goal is to see which approach better improves uri…

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The tria…

This early-stage trial tests a type of targeted radiation therapy for metastatic neuroendocrine prostate cancer, a rare and aggressive form of the disease. The treatment uses imaging to find specific markers on tumor cells and then delivers radiation directly to those cells. The …

This study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for sur…

This study tests whether a radioactive drug called radium-223 works better than standard hormone-blocking pills (ARPI) for men with prostate cancer that has spread to the bones and is no longer responding to initial hormone therapy. About 654 participants will receive either radi…

This phase 2 trial is testing several drug combinations—including niraparib, cetrelimab, abiraterone acetate, and prednisone—in 136 men with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has spread and stopped responding to standard hormone t…

This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at …

This study tests whether a surgery called retroperitoneal lymph node dissection (RPLND) can be used as the first treatment for men with early-stage testicular seminoma that has spread to lymph nodes in the abdomen. The goal is to see if this surgery can control the cancer while c…

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men whose prostate cancer has spread but still responds to hormones. About 1,140 men are taking part. The goal is to see if the combination slows cancer growth and exte…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug combination or a placebo. The goal is to see if the…

This study looks at how the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, taken together with prednisone. It involves 136 men with metastatic castration-resistant prostate cancer. The goal is to compare the absorption of various …

This phase 3 trial tests whether adding apalutamide (a hormone-blocking drug) to standard hormone therapy and radiation can delay the spread of prostate cancer in high-risk patients. About 1,500 men with localized or locally advanced prostate cancer are participating. The main go…

This early-stage study tests the drug apalutamide in 19 Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. Researchers want to see how the drug behaves in the body and if it is safe. They will also check if it lowers PSA levels, a marker of ca…

This phase 3 trial tests whether adding the drug niraparib to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 765 men with specific genetic changes are taking part. The study compa…

This study tests a new drug called JNJ-56021927 combined with abiraterone acetate (Zytiga) and prednisone in 57 men with metastatic castration-resistant prostate cancer. The goal is to see how these drugs interact, check safety, and get an early look at effectiveness. All partici…

This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…

This phase 2 trial tests whether a personalized walking program can slow the progression of localized prostate cancer in men who are on active surveillance (monitoring instead of immediate treatment). The 36 participants will exercise up to 5 times per week for 225-300 minutes to…

This study tests whether the drug apalutamide can delay prostate cancer progression in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread to other parts of the body. About 75 participants will receive either apalutamide or a placebo, alo…

This Phase 3 trial tests if men with metastatic prostate cancer who respond well to initial treatment with apalutamide and hormone therapy can safely pause the hormone therapy to reduce hot flashes. About 420 participants will be randomly assigned to continue or pause hormone the…

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants took ei…

This phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…

This phase 3 trial tests whether adding apalutamide (a daily pill) to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer live longer and delay disease progression. Over 1,000 participants received either apalutamide plus hormone therapy or a plac…

This phase 3 study tests whether adding the drug apalutamide to standard radiotherapy and hormone therapy can delay cancer spread or death in 692 men with high-risk prostate cancer. Participants are randomly assigned to receive either the standard treatment alone or with apalutam…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The m…

This study tests whether a drug called Xiaflex (collagenase clostridium histolyticum) is safe and effective for men with Peyronie's disease who have already tried platelet-rich plasma (PRP) injections. Twelve men with stable penile curvature between 30 and 90 degrees will receive…

This phase 2 trial is testing a drug called sacituzumab govitecan in 31 men with metastatic castration-resistant prostate cancer that has worsened despite hormone therapy. The drug works like a smart bomb, delivering chemotherapy directly to cancer cells. Researchers are measurin…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage study tests a new drug, JNJ-78278343, that helps the body's immune T-cells find and attack prostate cancer cells. It involves 216 men with advanced prostate cancer that has spread. The main goals are to find the safest and most effective dose and to monitor side …

This phase 3 trial tests whether adding apalutamide to standard treatment (abiraterone and prednisone) can delay cancer growth in men with advanced prostate cancer that no longer responds to hormone therapy. About 982 participants who have not had chemotherapy are randomly assign…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This phase 2 trial tests whether white button mushroom extract can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and not yet treated. About 133 men will take the supplement or be observed. The goal is to see if the mushroom affects …

This study tests two drugs—abiraterone and olaparib—alone or together in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Only men whose tumors have certain DNA repair defects (like BRCA or ATM mutations) are included. The goal is to se…

This phase 3 trial tests whether adding olaparib to standard abiraterone therapy helps men with metastatic castration-resistant prostate cancer live longer without their cancer worsening. About 895 men who have not had chemotherapy or newer hormone drugs for this stage will recei…

This early-phase trial tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified in a lab to recognize and attack cancer cells that carry a …

This phase 2 trial tests a DNA vaccine (pTVG-HP) plus the immunotherapy drug nivolumab in 19 men whose prostate cancer has returned after surgery but has not spread. The goal is to see if the combination can safely lower PSA levels to undetectable and delay cancer spread. Partici…

This study follows 60 men with an enlarged prostate who already used the Butterfly device for a year. Researchers will track safety and symptom relief for up to 5 years. The goal is to see if the device remains effective and safe over the long term.

This phase 2 trial studies whether adding radium-223 to enzalutamide works better than enzalutamide alone in men with castration-resistant prostate cancer that has spread to bones. Enzalutamide blocks male hormones that fuel cancer growth, while radium-223 delivers targeted radia…

This study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This early-phase study tests two drugs together—nivolumab (Opdivo) and Radium-223 (Xofigo)—in 39 men with metastatic castration-resistant prostate cancer that has spread to the bones. The main goals are to check safety and see if the combination can reduce tumor DNA in the blood.…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This study tests a radioactive drug (lutetium-177) alone or combined with newer hormone therapy in 49 men with a specific type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread on regular scans. The goal is to see if the treatment can lo…

This phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…

This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…

This phase II trial tests whether adding precise radiation (SBRT) to the hormone therapy darolutamide can delay cancer progression in men with castration-resistant prostate cancer that has only a few new spots of growth. The study involves 66 participants and measures how long it…

This Phase 3 trial tests whether adding the experimental drug saruparib to standard hormone therapy can slow cancer growth in men with metastatic prostate cancer that still responds to hormone treatment. About 1,889 men will receive either saruparib or a placebo, plus a hormone d…

This early-phase trial is testing whether giving an extra dose of the immunotherapy drug Sipuleucel-T can strengthen the immune system's attack on prostate cancer that has spread and stopped responding to hormone therapy. Fifteen men with this advanced cancer will receive three i…

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …

This study tests a newer, highly precise radiation technique for men with high-risk prostate cancer. The treatment delivers a strong dose to the pelvic lymph nodes while boosting radiation to the prostate itself. Researchers want to see if this approach controls the cancer better…

This study is testing whether adding an immunotherapy drug (ONC-392) to a targeted radiation therapy (Pluvicto) can help men with a hard-to-treat form of advanced prostate cancer. About 148 participants whose cancer has worsened despite standard treatments will receive either a l…

This study tests whether a Mediterranean diet is practical for medically underserved men with prostate cancer. Over 8 weeks, 25 participants receive fresh fruits, vegetables, olive oil, and walnuts, plus personalized education. The goal is to see if this diet is safe and feasible…

This Phase 3 trial compares two hormone therapies (GnRH antagonist vs GnRH agonist) given alongside radiation for men with very high-risk localized or locally advanced prostate cancer. The main goal is to see which combination better delays cancer progression. The study enrolled …

This early-phase trial tests a new treatment for castration-resistant prostate cancer (CRPC), a type that no longer responds to standard hormone therapy. Researchers are injecting specially engineered immune cells (CAR-T cells) directly into the prostate or tumor site, after a sh…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…

This phase 3 trial tests whether a shorter, higher-dose radiation schedule (hypofractionated) works as well as the standard longer course for men with prostate cancer who have had surgery. About 186 men will be randomly assigned to one of the two radiation plans. The study tracks…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39…

This phase 2 trial tests whether adding targeted radiation to standard hormone therapy can better control prostate cancer that has spread to a few spots in the body. About 29 men with hormone-sensitive prostate cancer and up to 5 metastases will receive hormone therapy (bicalutam…

This study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the standard drug enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while conti…

This study tests whether a new drug called xaluritamig helps people with advanced prostate cancer live longer compared to usual treatments (cabazitaxel or another hormone therapy). The trial includes about 700 adults whose cancer has spread and no longer responds to hormone thera…

This study aimed to see if giving the immunotherapy drug pembrolizumab before radical prostatectomy could reduce lymph node invasion in high-risk prostate cancer patients. Participants would have received three doses of the drug before surgery. However, the study was withdrawn be…

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 c…

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This phase 3 trial compares the standard chemotherapy docetaxel alone versus docetaxel plus radium-223 in 732 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if adding radium-223 helps patients…

This study looks at using heat or cold to destroy small clusters of prostate cancer that have spread to other parts of the body. It is for men who cannot have standard radiation therapy. The goal is to control the cancer with a quick, low-risk procedure that allows a fast recover…

This phase III trial compares two types of image-guided radiation for prostate cancer: CT-guided and MRI-guided stereotactic body radiotherapy (SBRT). About 179 men with localized prostate cancer will receive the same radiation dose, but one group's treatment is guided by CT scan…

This early-phase trial tests whether combining two oral targeted drugs, talazoparib and tazemetostat, is safe and can shrink or slow the growth of metastatic castration-resistant prostate cancer (mCRPC). About 35 adults with advanced prostate cancer that has spread and is no long…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…

This early-phase trial tests whether giving higher doses of radiation to the prostate in fewer sessions (while also treating pelvic lymph nodes) is safe for men with intermediate- to high-risk prostate cancer. The study enrolls 18 adults and uses proton beam therapy delivered fou…

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process that cancer cells rely on, especially those with certain DNA faults. The main goal is to see if the drug can…

This phase 2 trial tests a fixed-dose combination of niraparib and abiraterone acetate plus prednisone in 8 men with metastatic castration-resistant prostate cancer that has a SPOP gene mutation. The drugs work by blocking cancer cell repair and reducing inflammation. The main go…

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy (abiraterone, prednisone, and leuprolide) is safe and works better for men with newly diagnosed metastatic prostate cancer that hasn't been treated yet. T…

This phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…

This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can cont…

This trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolle…

This early-phase trial tests an investigational drug called ABBV-706, alone or combined with other drugs, in about 288 adults with advanced solid tumors like small cell lung cancer, high-grade brain tumors, and neuroendocrine cancers. The main goals are to check safety, find the …

This phase 3 trial tests whether adding radiation to the whole pelvis, along with standard hormone therapy and prostate radiation, helps men with intermediate- or high-risk prostate cancer live longer. About 2,590 men are taking part. The study compares standard treatment (hormon…

This study was designed to test a radioactive drug (177Lu-PSMA-617) in men with advanced prostate cancer that has spread to the bone marrow and caused low blood cell counts. The goal was to see if the treatment was safe and how it affected the cancer. However, the study was withd…

This study tests whether adding the drug darolutamide before and after surgery helps men with high-risk or locally advanced prostate cancer. About 240 men will either have surgery alone or surgery plus the drug. The goal is to see if the drug delays the cancer from coming back or…

This study tests whether a 16-week home-based high-intensity interval training (HIIT) program can slow prostate cancer in Black men who are on active surveillance (monitoring the cancer without immediate treatment). The trial involves 68 participants who will use a stationary bik…

This study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …

This Phase 3 trial tests whether adding the experimental drug mevrometostat to standard enzalutamide can slow cancer growth better than current treatments in men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants wil…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see i…

This phase 3 trial tests whether adding enzalutamide to standard hormone therapy and radiation can delay cancer spread in 802 men with high-risk localized prostate cancer. Participants receive either enzalutamide or a conventional anti-androgen alongside hormone therapy and radia…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from…

This study compares a new, less invasive treatment called Aquablation, which uses a high-speed waterjet to remove prostate tissue, to standard surgery (radical prostatectomy) for men with localized prostate cancer. About 280 men will be randomly assigned to one of the two treatme…

This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to combine three experimental drugs (N-803, ETBX-071, and M-CENK) with radiation to boost the immune system's attack on cancer. Researchers aimed to see if the treatment could elimi…

This study tests an experimental drug called ARV-766, taken as a pill, in men with prostate cancer that has spread to other parts of the body. The drug is given alone or with another medicine (abiraterone) to see if it is safe and can slow the cancer. About 152 men will take part…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men are participating in this phase 3 trial. The goal is to see if the combination helps keep the cance…

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery…

This study tests whether adding a hormone therapy to a targeted radiation drug (lutetium-177) is safe and effective for men with a certain type of advanced prostate cancer that has spread and stopped responding to hormone therapy alone. About 7 participants will receive either th…

This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. …

This small study tests whether a 3D ultrasound system can help doctors place extra radioactive iodine seeds precisely into prostate tumors. Fifteen men with low- or intermediate-risk prostate cancer will receive the boost during standard brachytherapy. The main goal is to see if …

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study wh…

This early-stage study tests a radioactive drug called 225Ac-PSMA-617 in men with PSMA-positive prostate cancer that has stopped responding to hormone therapy. The goal is to find a safe dose and see if it can help control the cancer, even in men who have already received a simil…

This study tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to see if it safely shrin…

This study tests a combination of two radiation techniques—brachytherapy and SBRT—guided by MRI for men with unfavorable prostate cancer. The goal is to achieve high cancer control rates while keeping serious side effects low. About 40 participants will be enrolled to see if this…

This early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects th…

This study looked at 70 men with an enlarged prostate and overactive bladder symptoms. Some received a Botox injection into the prostate during surgery, while others took standard medication after surgery. The Botox group showed better symptom scores at 12 weeks, suggesting a pot…

This early-phase trial tests whether a patient's own immune cells, modified to target a protein called PSMA on prostate cancer cells, are safe and can shrink tumors or lower PSA levels. It involves 7 to 18 men with metastatic castration-resistant prostate cancer that has stopped …

This study tests whether giving a mix of hormone-lowering medications (apalutamide, abiraterone, prednisone, and a GnRH drug) for a few months before surgery can shrink very high-risk prostate cancer and reduce the chance of it coming back. About 102 men with localized or low-vol…

This phase 2 trial is testing three different doses of a new drug called RS-113 in 120 men with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to standard hormone therapy. The study compares RS-113 to the current drug abiraterone to…

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This Phase 3 trial tests whether adding talazoparib to enzalutamide can slow the spread of metastatic castration-resistant prostate cancer (mCRPC). About 1,054 men with this advanced cancer are taking either the drug combo or a placebo plus enzalutamide. The study tracks how long…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can del…

This trial was designed to test whether robotic telesurgery—where a surgeon operates a robot from a different location—could safely treat prostate cancer using high-intensity focused ultrasound (HIFU). The study was withdrawn before enrolling any participants, so no data on safet…

This pilot study is testing a device that uses ultrasound images to guide a laser or freezing probe directly into prostate tumors. The goal is to destroy only the cancerous tissue while sparing healthy areas. Thirty men with low- to intermediate-risk prostate cancer that hasn't s…

This study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or …

This study tests whether stem cells from a patient's own bone marrow or fat can improve erectile dysfunction better than platelet-rich plasma or standard treatments. One hundred men with organic ED who did not respond to pills will receive one of these therapies. The goal is to s…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study compares two types of brachytherapy (radiation implants) for localized prostate cancer: low-dose-rate (seed) implants and high-dose-rate (temporary) implants. About 334 men will receive one of the two treatments. Researchers will measure how well each controls cancer a…

This study tests two treatments—isotretinoin (an acne medication) and hCG (a hormone)—to see if they can help men with low or no sperm count produce moving sperm. About 100 men aged 19 to 50 will take one of the drugs for three months. The goal is to find new options for male inf…

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…

This phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it…

This early study tests whether two drugs—denosumab and letrozole—can help men with a specific type of infertility (non-obstructive azoospermia) start producing sperm. Sixteen men will take the drugs for about three months, and researchers will check for sperm in their semen or te…

This study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…

This study tests whether giving a higher dose of radiation (up to 81 Gy) to men with high-risk prostate cancer can better control the disease without causing too many side effects. About 251 men who also need hormone therapy will receive targeted radiation using a precise techniq…

This study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including ovarian, endometrial, breast, and others) that have specific genetic changes or have stopped responding to similar treatments. The first phase finds…

This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naïve metastatic prostate cancer. The goal is to see how long patients can stay on treatment and how well it controls the cancer. All three drugs work by lowering or blocking…

This study compares two medications—gonadotropin and clomiphene citrate—to see which better improves sperm health in men with fertility problems. About 500 men with abnormal sperm analysis will be randomly assigned to one of the drugs. The goal is to measure changes in sperm coun…

This phase 2 trial tests whether combining golimumab (an anti-inflammatory drug) with apalutamide (a hormone blocker) can help men with castration-resistant prostate cancer that has spread. The study enrolled 8 participants and measures PSA reduction and tumor shrinkage. The goal…

This study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…

This study looks at whether a special gene test can help men with low-risk prostate cancer decide to monitor their cancer instead of treating it right away. About 805 men with early-stage prostate cancer will be randomly assigned to have the gene test or not. The goal is to see i…

This study tests a precise form of proton radiation for men with low- or intermediate-risk prostate cancer. The goal is to see if this approach causes fewer severe side effects than standard X-ray-based radiation. About 61 men will receive 5 treatments over 10 days and be monitor…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This study compares two ways of doing robotic prostate surgery in men with intermediate- to high-risk prostate cancer. One method enters from the back of the prostate, the other from the front. The goal is to see which approach better preserves urinary control and erectile functi…

This early-stage trial tests whether combining a targeted radiation drug (177Lu-PSMA-617) with chemotherapy (carboplatin) is safe and can shrink tumors in men with metastatic castration-resistant prostate cancer. About 37 men will receive the combination to find the best dose and…

This study follows nearly 1,000 prostate cancer patients taking ORGOVYX (relugolix) to see how the drug works in everyday medical practice. Researchers will track side effects, quality of life, and disease progression. The goal is to understand the drug's real-world safety and ef…

This was a phase 2 trial testing a combination of niraparib and abiraterone plus prednisone for metastatic hormone-sensitive prostate cancer in Hispanic/Latino and Black patients with specific gene mutations. The study aimed to enroll 64 people but was withdrawn before any partic…

This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage pros…

This phase 2 trial is testing a combination of radium-223 (a radioactive drug that targets bone tumors), hormone therapy, and precise radiation for men with prostate cancer that has spread to a few other places in the body. The goal is to see if this triple approach can delay can…

This study tests a new radioactive drug, FPI-2265, in 110 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy. Participants must have already received a similar radioactive treatment. The goal is to find the safest d…

This early-phase trial tests the safety and best dose of the chemotherapy drug eribulin when given with radiation therapy before surgery for retroperitoneal liposarcoma, a rare cancer that grows in the abdomen. About 15 patients will receive the combination to see how well they t…

This phase 2 trial tests whether a radioactive antibody called 177Lu-J591, combined with the hormone-blocking drug ketoconazole, can prevent prostate cancer from spreading in high-risk patients. The study enrolls 55 men whose PSA is rising despite hormone therapy but who have no …

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…

This study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…

This early-stage study tests a new radioactive drug called AB001 in 80 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful alpha radiation dose directly to cancer cells. The main goals are to check safety and find the bes…

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the c…

This observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall s…

This phase 2 trial tests a drug called FPI-2265, which delivers targeted radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The study will measure how w…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests whether a daily dose of green tea catechins (a natural compound) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are not receiving immediate treatment. Over 24 months, 115 men will receive either the green tea extract or a plac…

This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned t…

This study tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard radiation and hormone therapy is safe and effective for men with a very aggressive form of prostate cancer (Gleason grade group 5). About 44 men will receive the drug combination. The goal is to…

This study tests a new approach for men with stage IV prostate cancer that still responds to hormone therapy. Instead of continuous hormone treatment, doctors adjust the timing based on PSA levels and add chemotherapy. The goal is to see if this strategy can keep the cancer sensi…

This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409…

This phase 2 trial tests whether a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, can slow cancer growth better than standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has stopped responding to hormone therapy.…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone th…

This study tests whether a combination of two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the dru…

This phase 2 study tests a radioactive drug called Lu-PSMA-617 against standard hormone therapy in 63 Chinese men with advanced prostate cancer that has stopped responding to treatment. The drug targets cancer cells with radiation. The goal is to see if it can delay cancer growth…

This early study tests a new treatment called RT-310 for men with enlarged prostate (BPH) who have bothersome urinary symptoms. RT-310 is a drug delivered directly into the prostate to reduce side effects. The study will check if it is safe and feasible in 20 men aged 50 to 80.

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder surgery to prevent acute kidney injury. The surgery can reduce blood flow to the kidneys, and these drugs may help protect them. 90 adults with normal or mildly reduced kidney func…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before prostate removal surgery is safe and effective for men with high-risk prostate cancer. Sixteen men with aggressive prostate cancer (Gleason score 8 or higher or signs of spread) will receive ra…

This study tests whether taking apalutamide for 6 months before prostate removal surgery can reduce signs of aggressive cancer that often lead to radiation therapy afterward. It involves 45 men with intermediate-risk prostate cancer. The goal is to see if this approach can make s…

This study tests whether using a lung ultrasound during robotic prostate or bladder surgery can help doctors set the breathing machine to the right pressure, reducing lung collapse and other breathing problems. 88 adults with mild or no lung disease are enrolled. The approach is …

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This study tests whether a one-time procedure called brachytherapy, where tiny radioactive seeds are placed directly into the prostate, can control intermediate risk prostate cancer without needing additional treatments. Three hundred men with specific tumor features (Gleason sco…

This study tests whether a very short course of MRI-guided radiation (just 5 sessions) is safe and effective for men with low- or intermediate-risk prostate cancer. Traditional radiation can take 7-8 weeks, but this approach aims to cut that time dramatically. The trial involves …

This study tests whether using advanced MRI scans to guide radiation therapy can reduce side effects for men with localized prostate cancer. Depending on their MRI results, patients receive either a short course of radiation or a longer treatment with a targeted boost to visible …

This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study follows 3000 men with prostate cancer to compare how proton therapy and standard photon radiation affect quality of life and side effects like bowel urgency. Participants receive standard care at proton or photon centers, and researchers track bowel, urinary, and sexua…

This study tests different combinations of approved drugs in 196 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see which combinations work best to extend life and control the cancer. Participants receive standard hormo…

This study tests a radioactive drug (177Lu rhPSMA-10.1) alone or with hormone therapy in men with high-risk prostate cancer before they have surgery. The goal is to see if the drug is safe and can shrink the tumor. Only 6 men are taking part in this early-phase trial.

This study tests whether using MRI guidance to deliver an extra dose of radiation directly to the tumor can improve prostate cancer treatment. Forty men with localized prostate cancer will receive standard radiation to the whole prostate plus a targeted boost to the visible tumor…

This phase 2 study tests a combination of radiation, hormone therapy (ADT), and two drugs (abiraterone and olaparib) in 21 men with prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can prevent the cancer from growing or spreading fur…

This phase 2 trial tests whether a shorter, more intense radiation course (SBRT) causes fewer side effects than standard daily radiation (IMRT) in men with high-risk prostate cancer. Both groups also receive hormone therapy. The study will compare side effects, quality of life, a…

This study tests an experimental oral drug, MRT-2359, in adults with certain advanced cancers, including lung cancer, lymphoma, and other solid tumors driven by MYC genes. The first part finds the safest dose; the second part checks if the drug shrinks tumors. About 174 participa…

This phase 2 study tests pembrolizumab (Keytruda) in 40 men with metastatic castration-resistant prostate cancer that has specific genetic flaws (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors or slow the cancer. Researchers wi…

This study tests whether giving radiation in just 5 treatments over 2 weeks is as safe and effective as the standard 20 treatments over 4 weeks for men whose prostate cancer has come back after surgery. The 134 participants will be randomly assigned to one of the two schedules. T…

This early-phase study tests whether a bicalutamide implant placed directly into the prostate can replace standard hormone shots for men with localized prostate cancer receiving radiation. About 20 participants with intermediate- or high-risk cancer will receive the implant plus …

This phase 1 trial is testing a precise, high-dose radiation technique called SABR for men with high-risk prostate cancer. The goal is to find the highest safe dose to the prostate and pelvic lymph nodes while monitoring side effects. Sixty participants will receive five radiatio…

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI, can better control cancer while reducing side effects. About 164 men with prostate cancer will receive either the standard radiation or the standard plu…

This study tests a special type of radiation called stereotactic body radiotherapy (SBRT) for men with high-risk prostate cancer that hasn't spread. The treatment delivers a strong, focused dose of radiation to the tumor to kill cancer cells while sparing healthy tissue. Research…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will tak…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is testing a new way to detect prostate cancer by looking at cells in urine using a special imaging method. Researchers will collect urine samples from 675 men aged 50-75, including those with and without prostate cancer. The goal is to see if this simple test can accu…

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…

This study looks at whether a special PET scan called Axumin can find prostate cancer that has returned after treatment, even when another common scan (PSMA PET) shows nothing. About 50 adults with rising PSA levels and a negative PSMA PET will get an Axumin scan. The goal is to …

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study tests whether low-dose CT scans can detect testicular cancer recurrence as well as standard CT scans, but with much less radiation. About 251 men with stage I testicular cancer will be monitored using low-dose CT. If it works, patients could avoid the long-term risks o…

This study tests an artificial intelligence system that combines blood tests, lab data, and ultrasound images to better diagnose prostate cancer in men with borderline PSA levels (4-10 ng/mL). The goal is to reduce unnecessary biopsies by accurately identifying who truly has canc…

This study compares a new artificial intelligence (AI) system to radiologists for reading prostate MRI scans to detect cancer. About 130 men who are already scheduled for a prostate biopsy will have their MRI read by both the AI and a radiologist. The goal is to see if the AI can…

This study tests whether combining a special MRI analysis (called Habitat Risk Score) with blood and urine tests can more accurately rule out aggressive prostate cancer than the standard MRI reading. About 289 men with elevated PSA or abnormal exams will be enrolled. The goal is …

This study aimed to see if adding a two-minute distortion correction to standard prostate MRI scans could improve image quality and help doctors find tumors more accurately. It was designed for men who already had an MRI and biopsy. However, the study was withdrawn before any par…

This trial compares two biopsy methods for diagnosing prostate cancer in African American and white men with elevated PSA. One group gets a standard 12-core random biopsy, the other gets an MRI-guided fusion biopsy. The goal is to see which method more accurately detects clinical…

This study tests whether a new PET-CT scanner (RefleXion RMRS) can produce clear images of prostate cancer using a standard radioactive tracer. About 34 patients will receive both the standard scan and the new scan. If the new scanner works well, it may allow imaging and radiatio…

This study tests whether a special PET/CT scan (68Ga-PSMA-11) can help doctors plan more precise radiation for men whose prostate cancer has come back after surgery. About 193 men with a rising PSA level will be randomly assigned to have their radiation plan based on either the n…

This phase 3 study tests a new type of PET scan (64Cu-SAR-bisPSMA) to see if it can better detect prostate cancer that has come back after initial treatment. The study involves 220 adults with a rising PSA level after surgery or radiation. The goal is to improve detection so doct…

This study tests whether a new device called OmnEcoil can safely and effectively combine two separate prostate cancer tests—MRI and biopsy—into a single procedure. About 45 men aged 45 and older with elevated PSA or abnormal exams will participate. The goal is to see if this appr…

This study is testing a new imaging method called Cerenkov luminescence imaging, which uses light naturally given off by certain radioactive substances used in standard cancer scans. Researchers want to see if this technique can take clear pictures of thyroid cancer and tumors th…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study is testing whether a special MRI contrast called hyperpolarized pyruvate can help doctors see prostate tumors more clearly than standard MRI. About 130 men with prostate cancer will receive the contrast before imaging. The goal is to improve cancer detection and diagno…

This study tests a new 3D MRI technique to see if it can detect prostate cancer as well as or better than standard MRI, without needing an endorectal coil. It involves 33 men with untreated prostate cancer who are scheduled for surgery. The goal is to improve imaging comfort and …

This study tests whether a modified MRI scan (called Dixon sequencing) can produce clearer images of prostate cancer than the standard MRI. Researchers will compare the two methods in 65 men who have prostate cancer and are scheduled for prostate removal. The goal is to see if th…

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a sing…

This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biop…

This study looks at the best timing for a special PET scan (rhPSMA-7.3) to detect prostate cancer that has come back after prostate removal surgery. Men with a rising PSA level will get one or two scans to see when the cancer is most visible. The goal is to find the cancer early …

This study compares two types of urine samples—expressed prostatic secretion (EPS) and post-massage urine (PMU)—to see which one better predicts whether a prostate biopsy will find cancer. About 243 men scheduled for a prostate biopsy will provide both samples, and researchers wi…

This early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to …

This study is testing a new sperm quality test called SpermQT. It aims to see if the test can predict how likely a couple is to get pregnant with treatments like IUI or IVF. About 1,000 couples will take part, and researchers will track pregnancy outcomes based on the test result…

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how wel…

This pilot study is testing a new screening pathway for prostate cancer in men aged 55-65. Instead of relying only on PSA blood tests, participants with elevated PSA will also get a risk assessment and an MRI. The goal is to better distinguish between slow-growing cancers that do…

This study tests whether a special whole-body MRI (diffusion-weighted imaging) can better detect prostate cancer that has spread to bones or lymph nodes compared to standard bone scans and CT scans. About 98 men with high-risk prostate cancer will undergo all three imaging method…

This study looks at whether combining PSMA-PET/CT and MRI scans can more accurately determine the extent of prostate cancer in men with intermediate- or high-risk disease. Researchers will compare scan results with tissue samples from 600 men who had their prostate removed. The g…

This study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study looks at whether men with mild-to-moderate erectile dysfunction are more satisfied with sildenafil in a liquid suspension form compared to tablets that dissolve in the mouth. Researchers will review records of men who took each form for three months. The goal is to see…

This pilot study is testing a new device that uses pulsed field ablation to treat urinary symptoms caused by an enlarged prostate (BPH). About 100 men over age 45 who haven't gotten relief from medication will receive the treatment and be followed for safety and effectiveness. Th…

This study tests whether using advanced MRI and daily CT scans during radiation therapy for low- to intermediate-risk prostate cancer can reduce side effects like bowel, bladder, and erectile problems. About 99 men will receive standard radiation but with more precise imaging to …

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. Th…

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study tests whether eating a low-calorie diet before chemotherapy can reduce side effects like fatigue, nausea, and mouth sores, and also improve how well the treatment works. About 130 people with breast or prostate cancer will be randomly assigned to either follow the diet…

This study looks at whether men with prostate cancer can have robotic surgery to remove the prostate and go home the same day, instead of staying in the hospital overnight. Researchers will check how many patients agree to try this approach and how well it works. The goal is to s…

This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version tha…

This study compares standard robotic prostate cancer surgery with or without an extra step called vesicopexy, which repositions the bladder to its normal place. The goal is to see if this addition helps men regain bladder control faster and improves their quality of life. About 1…

This study tests a new device designed to relieve symptoms of an enlarged prostate, such as frequent or difficult urination. About 245 men aged 50 and older will be randomly assigned to receive the device or a sham procedure. The main goal is to see if the device improves symptom…

This study tests whether placing a cryopreserved umbilical cord allograft around nerves during robotic prostatectomy helps men regain erectile function and bladder control sooner. About 100 men with prostate cancer will be randomly assigned to receive either standard surgery or s…

This study compares group telemedicine appointments to individual video visits for men with prostate cancer who are on active surveillance. Researchers want to see if the group format is practical and acceptable, and how it affects patient satisfaction and quality of life. The st…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This study tests a new radiation technique for men whose prostate cancer returns after surgery. Instead of many standard treatments, this approach uses daily scans to adjust the radiation beam precisely, potentially reducing side effects and shortening the number of sessions. Abo…

This study tests a procedure called prostatic artery embolization (PAE) in 17 men with low-risk prostate cancer who also have trouble urinating. The goal is to see if PAE can reduce urinary symptoms before they start radiation therapy. Participants will have their symptoms and pr…

This study tests whether a personalized 4-week exercise program can improve quality of life and physical function in men with metastatic prostate cancer who are receiving radiation therapy. Eighty participants will either exercise or not, and researchers will track changes in wel…

This study tests whether combining platelet-rich plasma (PRP) injections with shock wave therapy can improve erections in men with moderate erectile dysfunction. 116 men will receive either the real treatment or a placebo over 9 weeks, then be followed for 6 months. The goal is t…

This study tests whether combining a stimulant drug (methylphenidate) with an exercise program can reduce severe fatigue in prostate cancer patients undergoing radiation and hormone therapy. About 200 participants will be assigned to drug plus exercise, drug alone, exercise alone…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer: proton therapy (PBT) and intensity-modulated radiation therapy (IMRT). Both are thought to be equally effective at treating the cancer, but it's unclear which causes fewer side effec…

This study looks at two non-drug ways to help older men with an enlarged prostate. It compares electromagnetic field therapy, a gentle treatment using energy waves, to aerobic exercise like walking or cycling. The goal is to see which works better to shrink the prostate and ease …

This study tests a device called the ProVee Urethral Expander, which is placed in the prostate to open the urinary channel and relieve symptoms of an enlarged prostate. About 221 men with moderate to severe symptoms are enrolled, and the device is compared to a sham procedure. Th…

This study looks at whether giving a numbing injection (called a TAP block) early or late during robotic prostate surgery helps reduce pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to lower pain scores and the need for stron…

This study looks at two procedures—prostate artery embolization (PAE) and holmium laser enucleation (HoLEP)—to see which better eases urinary symptoms caused by an enlarged prostate. It involves 45 men aged 50 or older with prostates larger than 80 grams. The main goal is to meas…

This study looks at whether people with breast or prostate cancer that has spread to the bones can safely stop or reduce their bone-strengthening medication after taking it for at least two years. The goal is to see if this change improves their quality of life without increasing…

This study tests a personalized rehabilitation program designed to help men recover their sexual quality of life after prostate removal for cancer. About 135 men will take part, with half receiving the program and half receiving standard care. The goal is to see if the program im…

This study aimed to see if a 12-week supervised exercise program could improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have been randomly assigned to either the supervised program or usual care with e…

This study tests a 3-month strength training program designed for Hispanic prostate cancer survivors and their caregivers. Participants exercise together in remote group classes to improve physical and mental health. The goal is to see if the program is practical and helpful for …

This study tests whether low-dose electrical stimulation of the pudendal nerve can improve erectile function in men with mild to moderate erectile dysfunction. Twenty-four men will receive a 20-minute stimulation session, and researchers will measure changes in erection hardness,…

This study looks at whether doing pelvic floor exercises before prostate surgery can help men avoid urine leakage afterward. About 30 men with an enlarged prostate will either do exercises before surgery or get standard care. The goal is to see if patients and doctors find the ex…

This study looks at whether giving men a deeper level of muscle relaxation during robotic prostate surgery can lower the pressure used during the operation and reduce pain afterward. About 139 men having this surgery will be randomly assigned to either deep or moderate muscle rel…

This study tests whether giving magnesium sulfate during prostate surgery can lower pain and reduce the need for strong painkillers. About 68 adults having robotic prostate surgery will either receive magnesium or not, as part of their standard anesthesia. Researchers will compar…

This trial tests whether having an empty bladder before CT simulation for prostate cancer radiation therapy is better than the usual full bladder. The goal is to see if it reduces urinary symptoms and makes daily treatments more consistent. About 168 men with prostate cancer will…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at how men with low-risk prostate cancer and their partners or close allies decide on treatment. Researchers want to understand how anxiety and uncertainty influence these choices. About 541 participants will fill out questionnaires about their feelings and prefe…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcome…

This study looks at prostate cancer tissue from men undergoing prostate removal surgery to find cells that may be especially aggressive and resistant to treatment. Researchers give a special dye (pimonidazole) before surgery to mark oxygen-starved areas, then analyze the removed …

This study tests a new type of MRI that uses a special substance (hyperpolarized pyruvate) to see how active prostate cancer tumors are. Researchers want to know if this scan can find aggressive cancers and show if treatments are working or stopping sooner than standard scans. Ab…

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…

This study looks at how men weigh the benefits of improved urination against changes in sexual function after a prostate surgery called HoLEP. Researchers will interview participants and ask them to complete questionnaires over two years. The goal is to understand what matters mo…

This study is testing whether artificial intelligence can predict if prostate cancer has spread to lymph nodes or other parts of the body by analyzing biopsy tissue images. Researchers will use samples from 3,000 men to develop and validate the AI model. The goal is to help docto…

This study is developing an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing a more severe form called castration-resistant prostate cancer. The AI will analyze MRI images, biopsy slides, and clinical data from…

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study tests whether an AI tool can help doctors quickly and fairly identify prostate cancer patients who might qualify for a clinical trial. Researchers will use AI to rank patient records by how well they match trial criteria, then check the results. The goal is to see if t…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This observational study is collecting data from Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. The main goal is to track heart-related side effects and other safety issues in r…

This study is a registry that collects information from over 1000 men who have surgery to get a penile implant for erectile dysfunction. The main goal is to measure how satisfied patients and their partners are after the procedure. The study does not test a new treatment, but rat…

This study looks at two methods for choosing which embryo to transfer during IVF: the standard way (looking at shape) and a newer way that also tracks how fast the embryo grows. The goal is to see which method leads to more live births. About 520 couples having their first or sec…

This study follows 214 men treated for prostate cancer to see how many develop lower limb lymphedema (leg swelling) and who is most at risk. Participants attend check-ups every three months for 18 months. The goal is to better understand this side effect and its impact on quality…

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…

This study looks at whether a blood test measuring the 'atherogenic index' can predict how well the drug tadalafil works for men with erectile dysfunction caused by blood vessel problems. Researchers will give 132 men tadalafil daily for one month and compare their symptom scores…

This study looks at how the severity of depression relates to erectile dysfunction and premature ejaculation in 100 married men aged 25–60 in the Sohag region of Egypt. Participants are clinically diagnosed with depression and sexually active. Researchers will use standard questi…

This study follows about 500 men with advanced prostate cancer that still responds to hormone therapy. Researchers are comparing two drug combinations (apalutamide or enzalutamide plus standard hormone therapy) to see how well they work in real-world settings. The goal is to unde…

This study uses a very powerful 7 Tesla MRI scanner to take detailed pictures of the brain in testicular cancer patients who have low testosterone (hypogonadism) and are on testosterone replacement therapy. The goal is to see if the MRI can detect changes in brain structure and f…

This study looks at how the experimental drug JNJ-56021927 changes the way the body processes several common medications in men with castration-resistant prostate cancer. About 23 participants will receive the cancer drug along with a cocktail of other drugs to measure how their …

This study tests whether a program that educates and supports doctors can help them follow national guidelines for prostate cancer imaging. About 58 VA doctors and staff took part. The goal is to reduce inappropriate scans for low-risk patients and ensure appropriate scans for hi…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This pilot study looks at whether special scans (PSMA PET/MRI) and genetic tests can predict how well high-risk prostate cancer responds to hormone therapy and radiation. Thirty participants will be followed for up to 5 years. The goal is to find markers that identify poor respon…

This study tests whether artificial intelligence can help doctors outline the prostate on ultrasound images for a type of radiation treatment called brachytherapy. Thirty-six adults with prostate cancer will have their treatment plans made both with and without AI assistance. The…

This study looks at how a new, more sensitive type of PET scan (PSMA PET) affects the anxiety, decision-making, and quality of life of 350 men with prostate cancer. Participants will fill out surveys about their feelings and experiences over a year. The goal is to understand the …

This study involves 400 men with high-risk prostate cancer who have not yet received treatment. Researchers are using a special type of scan called PSMA PET to see if it can find cancer that has spread to lymph nodes or other parts of the body, which standard scans often miss. Th…

This study tests a small implantable device that is placed inside prostate tumors to see how they respond to different cancer drugs. About 35 men scheduled for prostate removal surgery will receive the device before their operation. The goal is to learn whether this approach is s…

This study aimed to see if a specially designed website could help men with low-risk prostate cancer understand their treatment options and feel more confident in their choices. The researchers planned to enroll patients and measure their knowledge and decision-making satisfactio…

This observational registry will follow 500 men with metastatic castration-resistant prostate cancer who are receiving PSMA theranostics (177Lu-PSMA) as part of their standard care. Researchers will track how well the treatment lowers PSA levels and monitor any serious side effec…

This study compares infection rates in 300 men undergoing transperineal prostate biopsy, half receiving antibiotics and half not. The goal is to see if omitting antibiotics is safe. If proven, it could reduce unnecessary antibiotic use and side effects.

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study, called PARADIGM, is not testing a new drug. Instead, it looks at whether analyzing DNA from a blood sample can tell doctors which standard treatment—like hormone therapy or chemotherapy—will work best for a patient with metastatic prostate cancer. Researchers will tak…

This study looks at the genetic reasons why some baby boys develop an inguinal hernia or have an undescended testicle. Researchers will collect tissue and blood samples from 60 boys having surgery to check for changes in three specific genes. The goal is to better understand thes…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. Researchers will ask 120 people who had surgery in the last year to fill out questionnaires about their medical costs, travel expenses, and support needs. The goal is to un…

This study tests a web-based tool called WellPrept that gives patients clear information before their urology procedures. Researchers want to see if it helps patients feel more confident and understand their condition better, and if it shortens clinic visits. About 300 men and wo…

This pilot study tests a new MRI technique that uses a special form of bicarbonate to measure how acidic prostate tumors are. Ten men with localized prostate cancer will receive an injection of hyperpolarized bicarbonate before an MRI scan. The goal is to see if this method is sa…

This study looks at how Spanish-speaking Latiné men cope after prostate cancer treatment, especially with issues like erectile dysfunction and urinary problems. Researchers will survey and interview 55 survivors to understand their needs and cultural barriers. The goal is to crea…

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men aged 65 and older with prostate cancer. Researchers will compare cognitive function over time between men starting hormone therapy, those who have never had it, and those who ha…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study follows 120 men who had robot-assisted surgery for prostate cancer to see how they are doing 10 years later. Researchers will check if the cancer has come back, how common incontinence and erectile dysfunction are, and how satisfied patients feel. The goal is to unders…

This study looked at whether regular screening tests for prostate, lung, colorectal, and ovarian cancers can help find cancer early and reduce deaths. Over 76,000 men and women took part, with some getting screened and others receiving usual care. The main goal was to see if scre…

This study looks at whether a special PET scan called Posluma can help doctors plan radiation therapy more precisely for prostate cancer. About 20 patients will get both a standard PET scan and an extra scan on the RefleXion X1 machine. The goal is to see if the new scan finds th…

This study tests whether a special PET scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if this scan …

This study is looking at tiny particles called extracellular vesicles that come from prostate cancer cells. Researchers want to see if levels of these particles in blood and urine can show how well surgery removed the cancer. They will compare samples from prostate cancer patient…

This study reviews medical records from about 400 couples where the male partner has a condition called non-obstructive azoospermia (NOA), meaning no sperm is found in the semen. All couples used IVF with a special sperm injection technique. The goal is to see if testing embryos …

This study tests a lifestyle program for African American men who have finished prostate cancer treatment and their spouses or partners. The goal is to see if the program can improve quality of life, diet, physical activity, and partner support. Only 6 participants were enrolled,…

This study collects information from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer (mHSPC). Researchers want to see how doctors actually combine treatments like hormone therapy, newer drugs, or chemotherapy in everyday practice. No new trea…

This study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study looks back at 40 men with early-stage prostate cancer to compare two standard treatments: open surgery to remove the prostate and radiation therapy. The goal is to see which approach better controls the tumor and prevents recurrence. The results may help guide future t…

This study follows 304 men in Martinique diagnosed with prostate cancer from 2020 onward. Researchers use digital questionnaires to track changes in quality of life, especially sexual and urinary issues. The goal is to gather data to improve care and reduce health gaps in the Car…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study looks at how hormone therapy (anti-androgen treatment) for prostate cancer affects the heart. Researchers will use heart MRI scans before and after 4-7 months of treatment in 23 men. The goal is to understand changes in heart function, not to treat the cancer itself.

This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart over time, and how factors like medical history, race, income, and access to…

This study looks at whether detailed analysis of MRI scans (called radiomics) can better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 men with prostate cancer who have an MRI before treatment. The goal is…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study follows 490 men with low-risk prostate cancer in Brazil to see how well active surveillance works. Active surveillance means closely monitoring the cancer instead of treating it right away. The goal is to learn how often the cancer changes and how many men avoid treatm…

This study looks at how often prostate cancer survivors experience faecal incontinence (loss of bowel control) after a specific type of radiation therapy. Researchers will track 200 survivors and measure the radiation dose received by the anal sphincter to see if higher doses lea…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study explores whether a genetic test can identify prostate cancer patients at higher risk for urinary side effects from radiation therapy. Researchers will track side effects in 208 men with early-stage prostate cancer who receive stereotactic radiation. The goal is to see …

This study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers will collect blood samples from 956 newly diagnosed patients and track who has a relapse. The goal is to see if this marker ca…

The RELIEF study was designed to compare different treatments for an enlarged prostate (BPH) in everyday medical practice. It planned to follow patients who received the UroLift implant, other surgeries, or medication/watchful waiting. However, the study was withdrawn before enro…

This study collects tissue, blood, and other fluid samples from men with prostate conditions, including those with no cancer, localized disease, or advanced stages. Researchers will analyze genetic changes and protein markers to understand why some men get prostate cancer, why so…

This study surveys 20 penile cancer patients who have had groin lymph node surgery at least 6 months ago. Researchers use questionnaires to learn about patients' experiences, needs, and symptoms. The goal is to find ways to improve care and education for future patients.

This pilot study tests whether a smartphone app called Prostate Cancer Genius can help African American men learn about prostate cancer and complete a home-based PSA test. Eighty men aged 55 to 69 from Oklahoma who haven't had a PSA test in two years will use either the new app o…

This study follows 250 men with prostate cancer who are receiving radiotherapy. Researchers want to see if a person's 'sense of coherence' — their ability to cope with stress — is linked to their quality of life and how they rate their own health. Participants fill out questionna…

This study looks at whether the Decipher test, which predicts how aggressive prostate cancer is, works the same for African-American men as for other men. The test was developed mainly from samples of European men, but African-American men have higher rates of prostate cancer and…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to build a biobank for research into how the cancer responds to radiation. No participants were enrolled, and the study was withdrawn before it began.

This study was designed to see how much information people with breast or prostate cancer can recall about their screening and diagnosis. Researchers planned to give participants access to their online medical records and then test if that helped them remember more accurately. Ho…

This study looks at how certain hormone therapies for advanced prostate cancer might affect memory, thinking, and brain structure. Researchers will use brain scans and thinking tests in 100 men to track changes over time. The goal is to understand which patients are more likely t…